Efficacy and Safety of a Novel Herbal Medicine in the Treatment of Irritable Bowel Syndrome: A Randomized Double-Blinded Clinical Trial
Table 2
The mean scores of daily symptoms and stool consistency. Intention-to-treat population.
Group
Mean baseline (±s.d.)
Mean week 2 (±s.d.)
Mean CBTW2 (±s.d.)
Daily abdominal pain frequency per week
Control ()
4.8 (1)
0.58
3 (1.8)¶
1.8 (1.8)
Intervention ()
4.9 (0.9)
1 (1.2)¶
3.8 (1.4)
Daily abdominal bloating frequency per week
Control ()
4.9 (1.2)
0.61
2.9 (1.7)¶
2 (1.7)
Intervention ()
5 (1)
0.8 (1.1)¶
4.2 (1.6)
Stool frequency per day
IBS-D
Control ()
4 (0.4)
0.47
3.2 (0.4)
0.7 (0.5)
Intervention ()
4.2 (0.6)
2.2 (0.3)
1.9 (0.7)
IBS-C
Control ()
0.8 (0.4)
0.66
0.9 (0.2)
0.04 (0.2)
Intervention ()
0.7 (0.3)
1.8 (0.7)
1 (0.5)
IBS-M/U
Control ()
2.6 (0.5)
0.37
1.9 (0.2)
0.6 (0.5)
Intervention ()
2.7 (0.6)
2.5 (0.4)
0.1 (0.7)
Stool consistency
IBS-D
Control ()
5.1 (0.56)
0.68
4.6 (0.42)
0.4 (0.3)
Intervention ()
5.2 (0.6)
4.3 (0.11)
0.8 (0.5)
IBS-C
Control ()
3 (0.31)
0.78
3 (0.12)
0.01 (0.3)
Intervention (n = 8)
2.9 (0.30)
3.6 (0.49)
0.6 (0.3)
IBS-M/U
Control ()
4.1 (0.22)
0.51
3.6 (0.37)
0.4 (0.5)
Intervention ()
4 (0.37)
4.1 (0.18)
0.09 (0.3)
: value; mean CBTW2: mean change baseline to week 2; control: hyoscine; intervention: herbal medicine. , control vs. intervention; , control vs. intervention; , control vs. intervention; ¶, week 2 vs. baseline.
